ImmunoPrecise Antibodies Ltd. Expected to Post Q2 2025 Earnings of ($0.05) Per Share (NASDAQ:IPA)

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) – Investment analysts at HC Wainwright reduced their Q2 2025 earnings estimates for shares of ImmunoPrecise Antibodies in a research report issued to clients and investors on Tuesday, September 17th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.05) per share for the quarter, down from their previous estimate of ($0.04). HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for ImmunoPrecise Antibodies’ current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for ImmunoPrecise Antibodies’ Q3 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.30) EPS and FY2026 earnings at ($0.16) EPS.

ImmunoPrecise Antibodies (NASDAQ:IPA) last issued its quarterly earnings data on Monday, July 29th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.42). The company had revenue of $4.76 million during the quarter, compared to analysts’ expectations of $4.92 million. ImmunoPrecise Antibodies had a negative net margin of 110.66% and a negative return on equity of 57.05%.

Separately, Benchmark reduced their price objective on shares of ImmunoPrecise Antibodies from $5.00 to $3.00 and set a “speculative buy” rating on the stock in a report on Wednesday, August 14th.

ImmunoPrecise Antibodies Stock Up 1.5 %

Shares of IPA opened at $0.67 on Thursday. The firm has a market cap of $17.63 million, a P/E ratio of -1.61 and a beta of 0.10. ImmunoPrecise Antibodies has a 12-month low of $0.53 and a 12-month high of $2.60. The company’s 50-day moving average price is $0.79 and its 200 day moving average price is $1.09. The company has a current ratio of 1.41, a quick ratio of 1.15 and a debt-to-equity ratio of 0.36.

Institutional Trading of ImmunoPrecise Antibodies

An institutional investor recently raised its position in ImmunoPrecise Antibodies stock. Renaissance Technologies LLC grew its holdings in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 70.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 63,910 shares of the company’s stock after purchasing an additional 26,310 shares during the period. Renaissance Technologies LLC owned about 0.24% of ImmunoPrecise Antibodies worth $65,000 as of its most recent SEC filing. 6.70% of the stock is owned by institutional investors.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.